Acticor: a call for tenders to pursue development

(CercleFinance.com) - Acticor Biotech shares were up on the Paris Bourse on Friday, following the launch of a call for bids in connection with the company's receivership proceedings.


The biopharmaceutical company states that the call for bids, open until October 15, concerns the presentation of a continuation plan, or failing that, a sale plan to one or more buyers.

Acticor is looking for new investors following the failure, this spring, of its phase 2/3 clinical trial in the treatment of stroke, which resulted in the opening of receivership proceedings.

On October 3, the Paris Commercial Court will rule on the extension of these proceedings, with the aim of evaluating all possible solutions for continuing the company's development.

Acticor - the originator of glenzocimab, a humanized monoclonal antibody fragment for the treatment of cardiovascular emergencies and acute thrombotic diseases - estimates that it will be able to finance its operations until January 2025.

At the time of its last listing, at 11:40 a.m., the stock was up by over 28%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.